CSTL

Over the past six months, Castle Biosciences' stock price increased by 46.76% from September 22, 2025, to September 18, 2026, reaching $35.34 per share, with a 52-week range of $18.15 to $43.04 as of October 2, 2026. The 1-year change in stock price was +45.5% as of October 9, 2026, and the stock was trading above its 50-day and 200-day moving averages. On May 7, 2026, the stock experienced its largest daily move with a -22.3% close. The company held its Q1 2026 Earnings Call on May 6, 2026, and Q2 2026 Earnings Call on July 30, 2026. In August 2026, Castle Biosciences announced a dual listing on Nasdaq Texas while maintaining its primary listing on The Nasdaq Global Market, and also raised its outlook after reporting Q2 2026 revenue of $103.5 million, a 20% increase year-over-year, driven by DecisionDx-Melanoma and TissueCypher tests. The CEO, Derek J. Maetzold, exercised options and sold shares on October 5, 2026, under a Rule 10b5-1 plan. The company also participated in several investor conferences, including the Jefferies Global Healthcare Conference, Canaccord Genuity 46th Annual Growth Conference, and Baird's 2026 Global Healthcare Conference.